Related references
Note: Only part of the references are listed.Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses
Michael Kalos
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells
Cor H. J. Lamers et al.
BLOOD (2011)
Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy
Christian S. Hinrichs et al.
BLOOD (2011)
Redirected tumor-specific allogeneic T cells for universal treatment of cancer
Assaf Marcus et al.
BLOOD (2011)
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Renier J. Brentjens et al.
BLOOD (2011)
In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells
Shicheng Yang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB)
De-Gang Song et al.
CANCER RESEARCH (2011)
Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice
Christopher A. Klebanoff et al.
CLINICAL CANCER RESEARCH (2011)
Treatment of Advanced Leukemia in Mice with mRNA Engineered T Cells
David M. Barrett et al.
HUMAN GENE THERAPY (2011)
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
Barbara Savoldo et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Michael Kalos et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CDI9-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
Michael C. Jensen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer et al.
BLOOD (2010)
Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor
Yangbing Zhao et al.
CANCER RESEARCH (2010)
Building Better Chimeric Antigen Receptors for Adoptive T Cell Therapy
John S. Bridgeman et al.
CURRENT GENE THERAPY (2010)
Adoptive T cell therapy of cancer
Malcolm K. Brenner et al.
CURRENT OPINION IN IMMUNOLOGY (2010)
Integrase-defective lentiviral vectors: progress and applications
M. B. Banasik et al.
GENE THERAPY (2010)
The Optimal Antigen Response of Chimeric Antigen Receptors Harboring the CD3ζ Transmembrane Domain Is Dependent upon Incorporation of the Receptor into the Endogenous TCR/CD3 Complex
John S. Bridgeman et al.
JOURNAL OF IMMUNOLOGY (2010)
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
V. Hoyos et al.
LEUKEMIA (2010)
Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial
Renier Brentjens et al.
MOLECULAR THERAPY (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
Chimeric Receptor mRNA Transfection as a Tool to Generate Antineoplastic Lymphocytes
Peter M. Rabinovich et al.
HUMAN GENE THERAPY (2009)
Fifteen Years of Gene Therapy Based on Chimeric Antigen Receptors: Are We Nearly There Yet?''
Gianpietro Dotti et al.
HUMAN GENE THERAPY (2009)
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study
Fabio Ciceri et al.
LANCET ONCOLOGY (2009)
Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
Michael C. Milone et al.
MOLECULAR THERAPY (2009)
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
Carmine Carpenito et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity
Christian S. Hinrichs et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Graft-versus-leukemia effects of transplantation and donor lymphocytes
Hans-Jochem Kolb
BLOOD (2008)
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Brian G. Till et al.
BLOOD (2008)
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Martin A. Pule et al.
NATURE MEDICINE (2008)
Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo
Cor H. J. Lamers et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Chimeric NKG2D-Modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways
Tong Zhang et al.
CANCER RESEARCH (2007)
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts
Renier J. Brentjens et al.
CLINICAL CANCER RESEARCH (2007)
T cell activation by antibody-like immunoreceptors: The position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells
Andreas A. Hombach et al.
JOURNAL OF IMMUNOLOGY (2007)
Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma
Julie R. Park et al.
MOLECULAR THERAPY (2007)
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
Michael H. Kershaw et al.
CLINICAL CANCER RESEARCH (2006)
Synthetic messenger RNA as a tool for gene therapy
Peter M. Rabinovich et al.
HUMAN GENE THERAPY (2006)
Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells
A. Loskog et al.
LEUKEMIA (2006)
Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice
JA Westwood et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Supernatural T cells: Genetic modification of T cells for cancer therapy
MH Kershaw et al.
NATURE REVIEWS IMMUNOLOGY (2005)
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells
MA Pulè et al.
MOLECULAR THERAPY (2005)
Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy
T Zhang et al.
BLOOD (2005)
The role of extracellular spacer regions in the optimal design of chimeric immune receptors - Evaluation of four different scFvs and antigens
RD Guest et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation
D Friedmann-Morvinski et al.
BLOOD (2005)
Gene modification strategies to induce tumor immunity
A Murphy et al.
IMMUNITY (2005)
Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells
KS Kahlon et al.
CANCER RESEARCH (2004)
Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes
MWL Teng et al.
HUMAN GENE THERAPY (2004)
Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain
HM Finney et al.
JOURNAL OF IMMUNOLOGY (2004)
Safety of retroviral gene marking with a truncated NGF receptor
C Bonini et al.
NATURE MEDICINE (2003)
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15
RJ Brentjens et al.
NATURE MEDICINE (2003)
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
S Hacein-Bey-Abina et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Targeting tumours with genetically enhanced T lymphocytes
M Sadelain et al.
NATURE REVIEWS CANCER (2003)
Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors
NM Haynes et al.
BLOOD (2002)
Comparison of the TCR ζ-chain with the FcR γ-chain in chimeric TCR constructs for T cell activation and apoptosis
L Ren-Heidenreich et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR zeta/CD28 receptor
J Maher et al.
NATURE BIOTECHNOLOGY (2002)
Functional expression of chimeric receptor genes in human T cells
Z Eshhar et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2001)
Redirecting mouse CTL against colon carcinoma: Superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma
NM Haynes et al.
JOURNAL OF IMMUNOLOGY (2001)
Dynamics of tumor cell killing by human T lymphocytes armed with an anti-carcinoembryonic antigen chimeric immunoglobulin T-cell receptor
EJ Beecham et al.
JOURNAL OF IMMUNOTHERAPY (2000)
Share Paper
